Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991640211> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2991640211 abstract "Background: Bedaquline (BDQ) plays a key role in the treatment for multidrug- and extensively drug-resistant tuberculosis (M/XDR-TB). The presence of drug resistance-associated variants (RAVs) as wild mutant strains are widely known. To obtain the resistant rate of BDQ for the patients without prior drug use in Japan, drug susceptibility testing using phenotypic and molecular methods (pDST/gDST) of clinical isolates were examined. Methods: A total of 178 M. tuberculosis isolates was collected from M/XDR-TB patients in Osaka Habikino Medical Center from 1998 to 2016. MGIT AST for BDQ and clofazimine (CFZ), the minimum inhibitory concentrations (MICs) for BDQ, and proportion method or MGIT AST for the diagnosis of M/XDR-TB were conducted from cloning strains. For the gDST, the whole genome sequencing was conducted using MiSeq (illumine), and RAVs in RV0678, atpE and pepQ were examined using TGS-TB (https://gph.niid.go.jp/tgs-tb/). As a control group, the RAVs of the drug susceptible isolates from TB survey of resistance in Japan, 2007 [RYOKEN. Int J Tuberc Lung Dis 2015:19(2):157-62] were determined. Results: 178 isolates included 135 M/XDR-TB. 16/178 (9.0%) RAVs in RV0678, atpE and pepQ were detected, and 7 of 10 mutated isolates in RV0678 showed high BDQ MIC (0.25-1.0 µg/ml) and BDQ resistance. 5 of 7 BDQ resistant isolates showed CFZ resistance. 1 of 106 nonmutated strains in RV0678 showed high BDQ MIC, but it was susceptible of MGIT AST. 106 control susceptible strains have only 1 (0.9%) RAVs in RV0678. Conclusion: Our data suggested that DST for BDQ and CFZ might be necessary for MDR/XDR-TB before the treatment." @default.
- W2991640211 created "2019-12-05" @default.
- W2991640211 creator A5003475748 @default.
- W2991640211 creator A5003529366 @default.
- W2991640211 creator A5014868872 @default.
- W2991640211 creator A5030823210 @default.
- W2991640211 creator A5033788592 @default.
- W2991640211 creator A5034002948 @default.
- W2991640211 creator A5035564080 @default.
- W2991640211 creator A5050014937 @default.
- W2991640211 creator A5051881494 @default.
- W2991640211 creator A5072217209 @default.
- W2991640211 creator A5074060649 @default.
- W2991640211 creator A5091734402 @default.
- W2991640211 date "2019-09-28" @default.
- W2991640211 modified "2023-09-27" @default.
- W2991640211 title "Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan" @default.
- W2991640211 doi "https://doi.org/10.1183/13993003.congress-2019.oa2137" @default.
- W2991640211 hasPublicationYear "2019" @default.
- W2991640211 type Work @default.
- W2991640211 sameAs 2991640211 @default.
- W2991640211 citedByCount "0" @default.
- W2991640211 crossrefType "proceedings-article" @default.
- W2991640211 hasAuthorship W2991640211A5003475748 @default.
- W2991640211 hasAuthorship W2991640211A5003529366 @default.
- W2991640211 hasAuthorship W2991640211A5014868872 @default.
- W2991640211 hasAuthorship W2991640211A5030823210 @default.
- W2991640211 hasAuthorship W2991640211A5033788592 @default.
- W2991640211 hasAuthorship W2991640211A5034002948 @default.
- W2991640211 hasAuthorship W2991640211A5035564080 @default.
- W2991640211 hasAuthorship W2991640211A5050014937 @default.
- W2991640211 hasAuthorship W2991640211A5051881494 @default.
- W2991640211 hasAuthorship W2991640211A5072217209 @default.
- W2991640211 hasAuthorship W2991640211A5074060649 @default.
- W2991640211 hasAuthorship W2991640211A5091734402 @default.
- W2991640211 hasConcept C114851261 @default.
- W2991640211 hasConcept C142724271 @default.
- W2991640211 hasConcept C159047783 @default.
- W2991640211 hasConcept C203014093 @default.
- W2991640211 hasConcept C2776297342 @default.
- W2991640211 hasConcept C2777975735 @default.
- W2991640211 hasConcept C2780035454 @default.
- W2991640211 hasConcept C2780544761 @default.
- W2991640211 hasConcept C2780695269 @default.
- W2991640211 hasConcept C2781069245 @default.
- W2991640211 hasConcept C71924100 @default.
- W2991640211 hasConcept C86803240 @default.
- W2991640211 hasConcept C89423630 @default.
- W2991640211 hasConcept C98274493 @default.
- W2991640211 hasConceptScore W2991640211C114851261 @default.
- W2991640211 hasConceptScore W2991640211C142724271 @default.
- W2991640211 hasConceptScore W2991640211C159047783 @default.
- W2991640211 hasConceptScore W2991640211C203014093 @default.
- W2991640211 hasConceptScore W2991640211C2776297342 @default.
- W2991640211 hasConceptScore W2991640211C2777975735 @default.
- W2991640211 hasConceptScore W2991640211C2780035454 @default.
- W2991640211 hasConceptScore W2991640211C2780544761 @default.
- W2991640211 hasConceptScore W2991640211C2780695269 @default.
- W2991640211 hasConceptScore W2991640211C2781069245 @default.
- W2991640211 hasConceptScore W2991640211C71924100 @default.
- W2991640211 hasConceptScore W2991640211C86803240 @default.
- W2991640211 hasConceptScore W2991640211C89423630 @default.
- W2991640211 hasConceptScore W2991640211C98274493 @default.
- W2991640211 hasLocation W29916402111 @default.
- W2991640211 hasOpenAccess W2991640211 @default.
- W2991640211 hasPrimaryLocation W29916402111 @default.
- W2991640211 hasRelatedWork W18054434 @default.
- W2991640211 hasRelatedWork W19054850 @default.
- W2991640211 hasRelatedWork W19320763 @default.
- W2991640211 hasRelatedWork W2172546 @default.
- W2991640211 hasRelatedWork W36042 @default.
- W2991640211 hasRelatedWork W4136204 @default.
- W2991640211 hasRelatedWork W4537230 @default.
- W2991640211 hasRelatedWork W4570035 @default.
- W2991640211 hasRelatedWork W4697315 @default.
- W2991640211 hasRelatedWork W5163001 @default.
- W2991640211 isParatext "false" @default.
- W2991640211 isRetracted "false" @default.
- W2991640211 magId "2991640211" @default.
- W2991640211 workType "article" @default.